Labfit takes part in nanotechnology DREAM of UT Austin Portugal Program
DREAM stands for "Drug delivery nanosystem for HPV infection therapy Nanotechnologies", an exploratory research in the area of nanotechnologies, which have emerged as a potential therapeutic approach to viral infection and cancer treatment, specifically, DNA-based nanoparticles for antiviral and/or anticancer drugs greatly enhance their bioavailability and increase their target specificity.
This research led by Carla Cruz from the Beira Interior University and Andrew Ellington from the College of Natural Sciences of the University of Texas - Austin has shed a light on new therapeutic strategies against HPV infection and it is sponsored by the UT Austin Portugal Program, a multidisciplinary partnership between the University of Texas at Austin (UT Austin) and the Portuguese Foundation for Science and Technology (FCT), in close collaboration with the Instituto Superior Técnico Association for Research and Development (IST-ID) Cova da Beira Hospital Centre (CHCB) and Labfit – Health Products Research and Development Lda (HPRD Lda).
Know more about the project here: https://utaustinportugal.org/projects/dream-drug-delivery-nanosystem-for...
Dream poster here: https://utaustinportugal.org/wp-content/uploads/2020/09/dream.pdf
E-poster video here: https://www.youtube.com/watch?v=8AMY8Xfpa0Y